Floatz logo

FILGRASTIM

Metastatic Microsatellite Stable Colorectal Carcinoma

Roswell Park Cancer Instituteprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Metastatic Microsatellite Stable Colorectal Carcinoma cohort.

Asset / SponsorPhaseRating
Encorafenib
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2B
Balstilimab
City of Hope Medical Center
Phase 2B
Botensilimab
City of Hope Medical Center
Phase 2B
Abemaciclib
National Cancer Institute (NCI)
Phase 1/2CCC
Gm-Csf
Roswell Park Cancer Institute
Phase 2CCC
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN) (HUMAN-MUS MUSCULUS MONOCLONAL CAN04 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CAN04 .KAPPA.-CHAIN, DIMER
Dan Feng
Phase 1/2CCC
Guadecitabine
University of Southern California
Phase 1/2CC
Polypepi1018
Mayo Clinic
Phase 1CC

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →